Date: 2013-05-07
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of pre-clinical studies
Company: Ablynx (Belgium)
Product: ALX-0962
Action
mechanism: ALX-0962 is a monovalent 26kD Nanobody which incorporates Ablynx\'s proprietary plasma half-life extension technology targeting serum albumin. It has a unique dual mode of action in which it binds with high affinity to immunoglobulin E (IgE) as well as displacing receptor bound IgE. As a result, it is a very potent inhibitor of the biological effects exerted by IgE. Its high solubility allows for convenient subcutaneous administration. ALX-0962 has been developed with the potential to treat a broader population of patients suffering from asthma in a more effective and more convenient way compared to currently available therapies.
Disease: severe allergic asthma
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country:
Trial details:
Latest
news: * On May 7, 2013, Ablynx has announced that it has initiated pre-clinical development of its anti-IgE Nanobody®, ALX-0962, for the treatment of severe allergic asthma, with the goal of commencing Phase I clinical development in the second half of 2014. Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®) because of their high IgE to body weight ratios. Furthermore, ALX-0962 has the potential to exhibit a better safety profile, have a faster onset of action and offer more convenient dosing regimens.
